Literature DB >> 29310892

Sarcopenia is not associated with morbidity, mortality, or recurrence after esophagectomy for cancer.

Steve R Siegal1, James P Dolan2, Elizabeth N Dewey3, Alexander R Guimaraes4, Brandon H Tieu5, Paul H Schipper6, John G Hunter7.   

Abstract

BACKGROUND: Sarcopenia is associated with increased morbidity and mortality in hepatic, pancreatic and colorectal cancer. We examined the effect of sarcopenia on morbidity, mortality, and recurrence after resection for esophageal cancer.
METHODS: Retrospective review of consecutive esophagectomies from 2010 to 2015. Computed tomography studies were analyzed for sarcopenia. Morbidity was analyzed using Fischer's test and survival data with Kaplan Meier curves.
RESULTS: The sarcopenic group (n = 127) had lower BMI, later stage disease, and higher incidence of neoadjuvant radiation than those without sarcopenia (n = 46). There were no differences in morbidity or mortality between the groups (p = .75 and p = .31, respectively). Mean length of stay was similar (p = .70). Disease free and overall survival were similar (p = .20 and p = .39, respectively).
CONCLUSION: There is no association between sarcopenia and increased morbidity, mortality and disease-free survival in patients undergoing esophagectomy for cancer. Sarcopenia in esophageal cancer may not portend worse outcomes that have been reported in other solid tumors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; Esophagectomy; Outcomes; Recurrence; Sarcopenia

Mesh:

Year:  2018        PMID: 29310892     DOI: 10.1016/j.amjsurg.2017.12.017

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Sarcopenia and Short-Term Outcomes After Esophagectomy: A Meta-analysis.

Authors:  Pei-Yu Wang; Li-Dong Xu; Xian-Kai Chen; Lei Xu; Yong-Kui Yu; Rui-Xiang Zhang; Hai-Bo Sun; Hui-Li Wu; Yin Li
Journal:  Ann Surg Oncol       Date:  2020-02-10       Impact factor: 5.344

2.  Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer.

Authors:  Camila T B Gabiatti; Mariane C L Martins; Daniela L Miyazaki; Leandro P Silva; Fabiana Lascala; Ligia T Macedo; Maria Carolina Santos Mendes; José Barreto Campello Carvalheira
Journal:  Cancer Med       Date:  2019-10-01       Impact factor: 4.452

3.  Sarcopenia after induction therapy is associated with reduced survival in patients undergoing esophagectomy for locally-advanced esophageal cancer.

Authors:  Connor J Wakefield; Fadi Hamati; Justin M Karush; Andrew T Arndt; Nicole Geissen; Michael J Liptay; Jeffrey A Borgia; Sanjib Basu; Christopher W Seder
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

4.  Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.

Authors:  Lucy X Ma; Kirsty Taylor; Osvaldo Espin-Garcia; Reut Anconina; Chihiro Suzuki; Michael J Allen; Marta Honorio; Yvonne Bach; Frances Allison; Eric X Chen; Savtaj Brar; Carol J Swallow; Jonathan Yeung; Gail E Darling; Rebecca Wong; Sangeetha N Kalimuthu; Raymond W Jang; Patrick Veit-Haibach; Elena Elimova
Journal:  Cancer Med       Date:  2020-12-09       Impact factor: 4.452

Review 5.  Current status of perioperative nutritional intervention and exercise in gastric cancer surgery: A review.

Authors:  Satoshi Ida; Koshi Kumagai; Souya Nunobe
Journal:  Ann Gastroenterol Surg       Date:  2021-10-26

6.  Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence.

Authors:  Yacine Zouhry; Abdelkader Taibi; Sylvaine Durand-Fontanier; Tiffany Darbas; Geraud Forestier; Jacques Monteil; Valérie Lebrun-Ly; Philippe Fayemendy; Sophie Leobon; Pierre Jesus; Elise Deluche
Journal:  BMC Cancer       Date:  2021-12-07       Impact factor: 4.430

7.  Association of Sarcopenia With Toxicity and Survival in Postoperative Recurrent Esophageal Squamous Cell Carcinoma Patients Receiving Chemoradiotherapy.

Authors:  Ying-Ying Xu; Xi-Lei Zhou; Chang-Hua Yu; Wan-Wei Wang; Fu-Zhi Ji; Dong-Cheng He; Wei-Guo Zhu; Yu-Suo Tong
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.